As shown in Figures 7A–D, EP4 agonist significantly ameliorated IRI-induced kidney injury and subsequent renal fibrosis, as evidenced by HE and Masson staining, Western blot and immunohistochemical analyses of the expressions of fibrosis markers (fibronectin and α-SMA). This evidence concerns the gene ACTA1 and renal fibrosis.